Octreotide 84-mg Subcutaneous Hydrogel Implant Prot # EN3332-301: Phase IIIB, Open- Label, Multicenter Study to Evaluate the Long Term Safety and Efficacy of an 84MG Octreotide Subcutaneous Hydrogel Implant in Subjects with Acromegaly

Project: Research project

Project Details

StatusFinished
Effective start/end date2/15/112/15/13

Funding

  • Endo Pharmaceuticals Inc (EN3332-301)